Rafael Amado - 03 Apr 2024 Form 4 Insider Report for Zai Lab Ltd (ZLAB)

Role
President, Head of Global Oncology Research and Development
Signature
/s/ Bruce Blefeld, Attorney-in-Fact
Issuer symbol
ZLAB
Transactions as of
03 Apr 2024
Net transactions value
+$55,123
Form type
4
Filing time
05 Apr 2024, 17:47:15 UTC
Previous filing
03 Apr 2024
Next filing
18 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZLAB American Depositary Shares Options Exercise $85,717 +5,391 +27% $15.90 25,484 03 Apr 2024 Direct F1, F2
transaction ZLAB American Depositary Shares Sale $30,594 -1,952 -7.7% $15.67 23,532 04 Apr 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZLAB Restricted Share Units Options Exercise $0 -5,391 -25% $0.000000 16,173 03 Apr 2024 American Depositary Shares 5,391 Direct F1, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2 ADSs acquired upon vesting of Restricted Share Units ("RSUs").
F3 These ADSs were sold automatically to cover taxes upon vesting of RSUs.
F4 Each RSU represents a contingent right to receive one ADS.
F5 The RSUs vest in equal annual installments over four years beginning on 04/03/2024, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.

Remarks:

President, Head of Global Oncology Research and Development